The full content of Annals is available to subscribers

Subscribe/Learn More  >
Original Research |

Ursodiol Prophylaxis against Hepatic Complications of Allogeneic Bone Marrow Transplantation: A Randomized, Double-Blind, Placebo-Controlled Trial

James H. Essell, MD; Mark T. Schroeder, MD; Glenn S. Harman, MD; Ronald Halvorson, MD; Vernon Lew, RPh; Natalie Callander, MD; Michael Snyder, MD; Stacey K. Lewis, MD; Jeffrey P. Allerton, MD; and James M. Thompson, DO
[+] Article, Author, and Disclosure Information

From Wilford Hall Medical Center, Lackland Air Force Base, Texas. Disclaimer: The views expressed in this article are those of the authors and do not reflect the official policy of the U.S. Department of Defense or other Departments of the U.S. Government. Grant Support: Summit Pharmaceuticals supplied the study drug and placebo. No financial assistance was provided. Requests for Reprints: James H. Essell, MD, Oncology-Hematology Care, Inc., 199 William H. Taft Road, Cincinnati, OH 45219. Current Author Addresses: Dr. Essell: Oncology-Hematology Care, Inc., 199 William H. Taft Road, Cincinnati, OH 45219.

Copyright ©2004 by the American College of Physicians

Ann Intern Med. 1998;128(12_Part_1):975-981. doi:10.7326/0003-4819-128-12_Part_1-199806150-00002
Text Size: A A A

Background: Hepatic complications are a major cause of illness and death after bone marrow transplantation.

Objective: To confirm the results of a pilot study that indicated that ursodiol prophylaxis could reduce the incidence of veno-occlusive disease of the liver.

Design: Randomized, double-blind, placebo-controlled study.

Setting: Tertiary care teaching hospital.

Patients: 67 consecutive patients undergoing transplantation with allogeneic bone marrow (donated by a relative) in whom busulfan plus cyclophosphamide was used as the preparative regimen and cyclosporine plus methotrexate was used to prevent graft-versus-host disease.

Intervention: Before the preparative regimen was started, patients were randomly assigned to receive ursodiol, 300 mg twice daily (or 300 mg in the morning and 600 mg in the evening if body weight was > 90 kg), or placebo.

Measurements: Patients were prospectively evaluated for the clinical diagnosis of veno-occlusive disease, the occurrence of acute graft-versus-host disease, and survival.

Results: The incidence of veno-occlusive disease was 40% (13 of 32 patients) in placebo recipients and 15% (5 of 34 patients) in ursodiol recipients (P = 0.03). Assignment to placebo was the only pretransplantation characteristic that predicted the development of veno-occlusive disease. The most significant predictor of 100-day mortality was the diagnosis of veno-occlusive disease. The difference in actuarial risk for hematologic relapse in patients with chronic myelogenous leukemia and nonhepatic toxicities between the two groups was not statistically significant (13% in the ursodiol group and 20% in the placebo group; P > 0.2).

Conclusion: Ursodiol prophylaxis seemed to decrease the incidence of hepatic complications after allogeneic bone marrow transplantation in patients who received a preparative regimen with busulfan plus cyclophosphamide.


Grahic Jump Location
Figure 1.
Survival rates.P

Survival rate at 100 days was 0.77 for patients receiving ursodiol and 0.59 for those receiving placebo ( = 0.19).

Grahic Jump Location




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $32.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.